VJOncology is committed to improving our service to you

ESMO 2019 | Atezolizumab and bevacizumab for upfront unresectable HCC

VJOncology is committed to improving our service to you

Michael Lee

Michael Lee, MD, of UNC Lineberger Cancer Center, Chapel Hill, NC, explains the efficacy and safety results for atezolizumab and bevacizumab for patients with previously untreated, unresectable hepatocellular carcinoma (NCT02715531). He goes onto discuss the IMbrave150 study (NCT03434379). This interview took place at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter